Top Markets
Coin of the day
Aeolus Pharmaceuticals, Inc. Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS
Rangering i aksjer #41596
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pulmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$15.21K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aeolus Pharmaceuticals, Inc. (AOLS)

Kategori

P/E-forhold for Aeolus Pharmaceuticals, Inc. (AOLS)
P/E-forhold per 2026 TTM: 0
Ifølge Aeolus Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Aeolus Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.